AbbVie (ABBV) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie
SHAREHOLDER ALERT: Weiss Law Investigates Landos Biopharma, Inc.
Landos Biopharma, Inc. (NASDAQ: LABP) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $20.42 price target on the stock, down previously from $50.00.
LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP